CAS: 845272-21-1; (R)-N4-(3-Chloro-4-(Thiazol-2-Ylmethoxy)Phenyl)-N6-(4-Methyl-4,5-Dihydrooxazol-2-yl)Quinazoline-4,6-Diamine

上下游产品

2-((2-chloro-4-nitrophenoxy)methyl)thiazole 3-chloro-4-(thiazol-2-ylmethoxy)aniline 4-N-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)quinazoline-4,6-diamine 2-amino-5-nitro-benzoic acid

📜6-硝基喹唑啉-4(3H)-酮置于copper(L) Iodide,均苯三甲酸,氢气,Caesium Carbonate,N,N-二甲基甲酰胺,锌体系中,用 四氢呋喃,乙醇,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 4.0H,反应生成 泛egfr小分子抑制剂(Varlitinib)
参考文献:一种治疗胆管癌的药物的制备方法
标题:一种治疗胆管癌的药物的制备方法
摘要:本发明属于医药工业领域,公开了一种治疗胆管癌的药物的制备方法;胆管癌治疗药物varlitinib的制备方法包括:由2‑氨基‑5‑硝基苯甲酸起始,经过醋酸甲咪环合,氯代合成中间体i;由2‑氯‑5‑硝基苯酚起始,经过2‑氯甲基噻唑取代,硝基还原合成中间体ii;由1‑氨基‑2‑丙醇为起始,通过btc的环合反应,氯代合成中间体iii;中间体i和中间体ii通过c‑n偶联,硝基还原,最后与中间体iii发生c‑n偶联反应后合成varlitinib.本发明方法合成简便,路线短,原料经济,产率高,环境友好,适合工业化反应生成.

专利信息

专利号:US-11406709-B2
优先权日:2014-09-15
标 题 :Therapeutic and research application of PDCL3
发明人：RAHIMI NADER
权利人:UNIV BOSTON
摘要:Described herein are novel compositions comprising, for example, PDCL3 polypeptides having VEGFR-2 inhibitory activity, inhibitory PDCL3 antibodies and PDCL3-binding fragments thereof, or PDCL3 inhibitory nucleic acid molecules, and methods of their use in anti-angiogenesis and anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, as well as the treatment of those vascular diseases where pathological angiogenesis plays a role, such as in carotid artery disease, macular degeneration, and plaque neovascularization. Also described herein are novel compositions comprising engineered PDCL3 polypeptides having enhanced chaperone activity, recombinant cells comprising such engineered PDCL3 polypeptides having enhanced chaperone activity, and methods thereof for therapeutic protein production and in vitro protein synthesis.

专利号:US-2022396794-A1
优先权日:2019-06-04
标题:APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
发明人：HABIB NAGY; ROSSI JOHN; YOON SORAH; SWIDERSK PIOTR MAREK
权利人:APTERNA LTD; HOPE CITY
摘要:Methods of treating or preventing a disease or disorder are disclosed comprising administering to a subject in need thereof an effective amount of a nucleic acid compound comprising, or consisting of, a nucleic acid sequence capable of binding to a transferrin receptor (TfR) and an effective amount of an inhibitor of DNA synthesis. Also disclosed is a nucleic acid compound comprising, or consisting of, a nucleic acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein said nucleic acid sequence is at least 30 nucleotides in length and at most 50 nucleotides in length, and wherein the nucleic acid sequence is capable of binding to a transferrin receptor (TfR).